{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T21:44:23Z","timestamp":1788212663832,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T00:00:00Z","timestamp":1726876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T00:00:00Z","timestamp":1726876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K17325"],"award-info":[{"award-number":["22K17325"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018502","name":"Kanazawa University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018502","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s40261-024-01383-x","type":"journal-article","created":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T06:02:05Z","timestamp":1726898525000},"page":"749-759","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparative Cost-Effectiveness of Atezolizumab Versus Durvalumab as First-Line Combination Treatment with Chemotherapy for Patients with Extensive-Disease Small-Cell Lung Cancer in Japan"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5178-611X","authenticated-orcid":false,"given":"Munenobu","family":"Kashiwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Tsukada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,21]]},"reference":[{"key":"1383_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"1383_CR2","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2188\/jea.JE20220302","volume":"33","author":"H Tanaka","year":"2023","unstructured":"Tanaka H, Tanaka S, Togawa K, Katanoda K. Practical implications of the update to the 2015 Japan standard population: mortality archive from 1950 to 2020 in Japan. J Epidemiol. 2023;33:372\u201380. https:\/\/doi.org\/10.2188\/jea.JE20220302.","journal-title":"J Epidemiol"},{"key":"1383_CR3","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1093\/jjco\/hyn072","volume":"38","author":"Y Toyoda","year":"2008","unstructured":"Toyoda Y, Nakayama T, Ioka A, Tsukuma H. Trends in lung cancer incidence by histological type in Osaka, Japan. Jpn J Clin Oncol. 2008;38:534\u20139. https:\/\/doi.org\/10.1093\/jjco\/hyn072.","journal-title":"Jpn J Clin Oncol"},{"key":"1383_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/pl00008483","volume":"126","author":"K Junker","year":"2000","unstructured":"Junker K, Wiethege T, M\u00fcller KM. Pathology of small-cell lung cancer. J Cancer Res Clin Oncol. 2000;126:361\u20138. https:\/\/doi.org\/10.1007\/pl00008483.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1383_CR5","unstructured":"Guidelines for Diagnosis and Treatment of Lung Cancer\/Malignant Pleural Mesothelioma\/Thymic Tumor 2023. https:\/\/www.haigan.gr.jp\/guideline\/2023\/. Accessed 10 July 2024."},{"key":"1383_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.21037\/tlcr.2018.01.16","volume":"7","author":"AF Farago","year":"2018","unstructured":"Farago AF, Keane FK. Current standards for clinical management of small cell lung cancer. Transl Lung Cancer Res. 2018;7:69\u201379. https:\/\/doi.org\/10.21037\/tlcr.2018.01.16.","journal-title":"Transl Lung Cancer Res."},{"key":"1383_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1054\/bjoc.2000.1164","volume":"83","author":"JL Pujol","year":"2000","unstructured":"Pujol JL, Carestia L, Daur\u00e8s JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer. 2000;83:8\u201315. https:\/\/doi.org\/10.1054\/bjoc.2000.1164.","journal-title":"Br J Cancer"},{"key":"1383_CR8","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1200\/JCO.1992.10.2.282","volume":"10","author":"BJ Roth","year":"1992","unstructured":"Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 1992;10:282\u201391. https:\/\/doi.org\/10.1200\/JCO.1992.10.2.282.","journal-title":"J Clin Oncol"},{"key":"1383_CR9","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1002\/cncr.23871","volume":"113","author":"YH Kim","year":"2008","unstructured":"Kim YH, Goto K, Yoh K, Niho S, Ohmatsu H, Kubota K, et al. Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy. Cancer. 2008;113:2518\u201323. https:\/\/doi.org\/10.1002\/cncr.23871.","journal-title":"Cancer"},{"key":"1383_CR10","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1809064.","journal-title":"N Engl J Med"},{"key":"1383_CR11","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(19)32222-6.","journal-title":"Lancet"},{"key":"1383_CR12","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1507643.","journal-title":"N Engl J Med"},{"key":"1383_CR13","doi-asserted-by":"publisher","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","volume":"20","author":"DS Ettinger","year":"2022","unstructured":"Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non-small cell lung cancer. Version 3. 2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2022;20:497\u2013530.","journal-title":"J Natl Compr Cancer Netw."},{"key":"1383_CR14","doi-asserted-by":"publisher","first-page":"5448","DOI":"10.1200\/JCO.23.01435","volume":"41","author":"H Khurshid","year":"2023","unstructured":"Khurshid H, Ismaila N, Bian J, Dabney R, Das M, Ellis P, et al. Systemic therapy for small-cell lung cancer: ASCO-Ontario health (cancer care Ontario) guideline. J Clin Oncol. 2023;41:5448\u201372. https:\/\/doi.org\/10.1200\/JCO.23.01435.","journal-title":"J Clin Oncol"},{"key":"1383_CR15","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","volume":"32","author":"AC Dingemans","year":"2021","unstructured":"Dingemans AC, Fr\u00fch M, Ardizzoni A, Besse B, Faivre-Finn C, Hendriks LE, et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:839\u201353. https:\/\/doi.org\/10.1016\/j.annonc.2021.03.207.","journal-title":"Ann Oncol"},{"key":"1383_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2019.01.019","volume":"130","author":"K Zhou","year":"2019","unstructured":"Zhou K, Zhou J, Huang J, Zhang N, Bai L, Yang Y, et al. Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer. Lung Cancer. 2019;130:1\u20134. https:\/\/doi.org\/10.1016\/j.lungcan.2019.01.019.","journal-title":"Lung Cancer"},{"key":"1383_CR17","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1097\/CM9.0000000000000536","volume":"132","author":"L-Y Li","year":"2019","unstructured":"Li L-Y, Wang H, Chen X, Li W-Q, Cui J-W. First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China. Chin Med J (Engl). 2019;132:2790\u20134. https:\/\/doi.org\/10.1097\/CM9.0000000000000536.","journal-title":"Chin Med J (Engl)"},{"key":"1383_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.650392","volume":"9","author":"Y Wang","year":"2021","unstructured":"Wang Y, Rui M, Yang L, Wang X, Shang Y, Ma A, et al. Economic evaluation of first-line atezolizumab for extensive-stage small-cell lung cancer in the US. Front Public Health. 2021;9: 650392. https:\/\/doi.org\/10.3389\/fpubh.2021.650392.","journal-title":"Front Public Health"},{"key":"1383_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.602185","volume":"10","author":"L Zhang","year":"2020","unstructured":"Zhang L, Hang Y, Liu M, Li N, Cai H. First-line durvalumab plus platinum-etoposide versus platinum-etoposide for extensive-stage small-cell lung cancer: a cost-effectiveness analysis. Front Oncol. 2020;10: 602185. https:\/\/doi.org\/10.3389\/fonc.2020.602185.","journal-title":"Front Oncol"},{"key":"1383_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/14737167.2021.1888717","volume":"22","author":"G Liu","year":"2022","unstructured":"Liu G, Kang S. Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China. Expert Rev Pharmacoecon Outcomes Res. 2022;22:85\u201391. https:\/\/doi.org\/10.1080\/14737167.2021.1888717.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1383_CR21","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.6004\/jnccn.2020.7796","volume":"19","author":"D Ding","year":"2021","unstructured":"Ding D, Hu H, Li S, Zhu Y, Shi Y, Liao M, et al. Cost-effectiveness analysis of durvalumab plus chemotherapy in the first-line treatment of extensive-stage small cell lung cancer. J Natl Compr Canc Netw. 2021;19:1141\u20137. https:\/\/doi.org\/10.6004\/jnccn.2020.7796.","journal-title":"J Natl Compr Canc Netw"},{"key":"1383_CR22","doi-asserted-by":"publisher","first-page":"e2013","DOI":"10.1002\/onco.13954","volume":"26","author":"S Lin","year":"2021","unstructured":"Lin S, Luo S, Gu D, Li M, Rao X, Wang C, et al. First-line durvalumab in addition to etoposide and platinum for extensive-stage small cell lung cancer: a US-based cost-effectiveness analysis. Oncologist. 2021;26:e2013\u201320. https:\/\/doi.org\/10.1002\/onco.13954.","journal-title":"Oncologist"},{"key":"1383_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/0300891620985309","volume":"108","author":"Y-H Tong","year":"2022","unstructured":"Tong Y-H, Ding H-Y, Xin W-X, Zhong L-K, Xu G-Q, Zhang B, et al. Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers\u2019 perspective. Tumori. 2022;108:33\u20139. https:\/\/doi.org\/10.1177\/0300891620985309.","journal-title":"Tumori"},{"key":"1383_CR24","unstructured":"Cancer survival in hospital-based cancer registries. Cancer Information Service, National Cancer Center, Japan. https:\/\/hbcr-survival.ganjoho.jp\/graph. Accessed 10 Jul 2024."},{"key":"1383_CR25","unstructured":"Guideline for preparing cost-effectiveness evaluation to the central social insurance medical council. version 3.0 [Internet]. Center for Outcomes Research and Economic Evaluation for Health. https:\/\/c2h.niph.go.jp\/tools\/guideline\/. Accessed 10 Jul 2024."},{"key":"1383_CR26","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2023. https:\/\/www.R-project.org\/. Accessed 10 July 2024."},{"key":"1383_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100353","volume":"3","author":"K Morimoto","year":"2022","unstructured":"Morimoto K, Yamada T, Takeda T, Shiotsu S, Date K, Harada T, et al. Efficacy and safety of programmed death-ligand 1 inhibitor plus platinum-etoposide chemotherapy in patients with extensive-stage SCLC: a prospective observational study. JTO Clin Res Rep. 2022;3: 100353. https:\/\/doi.org\/10.1016\/j.jtocrr.2022.100353.","journal-title":"JTO Clin Res Rep."},{"key":"1383_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051543","author":"T Takeda","year":"2023","unstructured":"Takeda T, Yamada T, Kunimatsu Y, Tanimura K, Morimoto K, Shiotsu S, et al. Age-stratified analysis of first-line chemoimmunotherapy for extensive-stage small cell lung cancer: real-world evidence from a multicenter retrospective study. Cancers. 2023. https:\/\/doi.org\/10.3390\/cancers15051543.","journal-title":"Cancers"},{"key":"1383_CR29","unstructured":"Reimbursement schedule of social insurance 2022. https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000188411_00037.html. Accessed 10 July 2024."},{"key":"1383_CR30","unstructured":"National health insurance drug price standard. https:\/\/www.mhlw.go.jp\/topics\/2022\/04\/tp20220401-01.html. Accessed 10 July 2024."},{"key":"1383_CR31","unstructured":"Ministry of Health, Labour and Welfare. Diagnostic Procedure Classification (DPC) electronic score table. https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000198757_00004.html. Accessed 10 July 2024."},{"key":"1383_CR32","unstructured":"JMDC claims database\u2014JMDC Inc. \u682a\u5f0f\u4f1a\u793e JMDC; 2021. https:\/\/www.jmdc.co.jp\/en\/jmdc-claims-database\/. Accessed 10 July 2024."},{"key":"1383_CR33","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/jjco\/hyy030","volume":"48","author":"O Miyake","year":"2018","unstructured":"Miyake O, Murata K, Tanaka S, Ishiguro H, Toi M, Tamura K, et al. Costs associated with febrile neutropenia in Japanese patients with primary breast cancer: post-hoc analysis of a randomized clinical trial. Jpn J Clin Oncol. 2018;48:410\u20136. https:\/\/doi.org\/10.1093\/jjco\/hyy030.","journal-title":"Jpn J Clin Oncol"},{"key":"1383_CR34","unstructured":"Conversion rates\u2014Exchange rates\u2014OECD Data. https:\/\/data.oecd.org\/conversion\/exchange-rates.htm. Accessed 10 July 2024."},{"key":"1383_CR35","unstructured":"Rohatgi A. WebPlotDigitizer\u2014Extract data from plots, images, and maps. https:\/\/automeris.io\/WebPlotDigitizer\/. Accessed 10 July 2024."},{"key":"1383_CR36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJNM, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan\u2013Meier survival curves. BMC Med Res Methodol. 2012;12:9. https:\/\/doi.org\/10.1186\/1471-2288-12-9.","journal-title":"BMC Med Res Methodol"},{"key":"1383_CR37","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1016\/j.cllc.2021.09.006","volume":"23","author":"N Kuehne","year":"2022","unstructured":"Kuehne N, Hueniken K, Xu M, Shakik S, Vedadi A, Pinto D, et al. Longitudinal assessment of health utility scores, symptoms and toxicities in patients with small cell lung cancer using real world data. Clin Lung Cancer. 2022;23:e154\u201364. https:\/\/doi.org\/10.1016\/j.cllc.2021.09.006.","journal-title":"Clin Lung Cancer"},{"key":"1383_CR38","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1477-7525-6-84","volume":"6","author":"B Nafees","year":"2008","unstructured":"Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. 2008;6:84. https:\/\/doi.org\/10.1186\/1477-7525-6-84.","journal-title":"Health Qual Life Outcomes"},{"key":"1383_CR39","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s11136-020-02615-1","volume":"30","author":"A Vedadi","year":"2021","unstructured":"Vedadi A, Shakik S, Brown MC, Lok BH, Shepherd FA, Leighl NB, et al. The impact of symptoms and comorbidity on health utility scores and health-related quality of life in small cell lung cancer using real world data. Qual Life Res. 2021;30:445\u201354. https:\/\/doi.org\/10.1007\/s11136-020-02615-1.","journal-title":"Qual Life Res"},{"key":"1383_CR40","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.cllc.2016.12.015","volume":"18","author":"C Labb\u00e9","year":"2017","unstructured":"Labb\u00e9 C, Leung Y, Silva Lemes JG, Stewart E, Brown C, Cosio AP, et al. Real-world EQ5D health utility scores for patients with metastatic lung cancer by molecular alteration and response to therapy. Clin Lung Cancer. 2017;18:388-395.e4.","journal-title":"Clin Lung Cancer"},{"key":"1383_CR41","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1111\/ajco.12477","volume":"13","author":"B Nafees","year":"2017","unstructured":"Nafees B, Lloyd AJ, Dewilde S, Rajan N, Lorenzo M. Health state utilities in non-small cell lung cancer: an international study. Asia Pac J Clin Oncol. 2017;13:e195-203. https:\/\/doi.org\/10.1111\/ajco.12477.","journal-title":"Asia Pac J Clin Oncol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01383-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-024-01383-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01383-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T16:18:23Z","timestamp":1729700303000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-024-01383-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,21]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1383"],"URL":"https:\/\/doi.org\/10.1007\/s40261-024-01383-x","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,21]]},"assertion":[{"value":"16 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding provided by Kanazawa University. This work was supported by the Japan Society for the Promotion of Science KAKENHI (Grant no: 22K17325).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The datasets generated and analysed during the current study are the corresponding author upon reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"This study did not include the use of human participants or animals.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The codes generated in the current study are the corresponding author upon reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The study was designed by M.K., and the first draft of the paper was written by M.T. R.M. provided guidance in proposing the structure of the paper, interpreting the results, and improving the overall quality of the paper. All authors contributed to gathering data and offer constructive feedback on the manuscript. They all agreed to be responsible for each component of the work and make sure that any questions about the accuracy or integrity of any part of it are properly investigated and resolved.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}